The Mechanism of Substrate
Inhibition in Human Indoleamine 2,3-Dioxygenase by Efimov, Igor et al.
The Mechanism of Substrate Inhibition in Human Indoleamine
2,3-Dioxygenase
Igor Efimov,
† Jaswir Basran,
‡ Xiao Sun,
† Nishma Chauhan,
† Stephen K. Chapman,
§
Christopher G. Mowat,
⊥ and Emma Lloyd Raven*
,†
†Department of Chemistry, University of Leicester, University Road, Leicester LE1 7RH, United Kingdom
‡Department of Biochemistry, University of Leicester, Lancaster Road, Leicester LE1 9HN, United Kingdom
§Heriot-Watt University, George Heriot Wing, Edinburgh EH14 4AS, United Kingdom
⊥EaStCHEM, School of Chemistry, University of Edinburgh, West Mains Road, Edinburgh EH9 3JJ, United Kingdom
* S Supporting Information
ABSTRACT: Indoleamine 2,3-dioxygenase catalyzes the
O2-dependent oxidation of L-tryptophan (L-Trp) to N-formylky-
nurenine (NFK) as part of the kynurenine pathway. Inhibi-
tion of enzyme activity at high L-Trp concentrations was
first noted more than 30 years ago, but the mechanism of
inhibition has not been established. Using a combination of
kinetic and reduction potential measurements, we present
evidence showing that inhibition of enzyme activity in human indoleamine 2,3-dioxygenase (hIDO) and a number of site-
directed variants during turnover with L-tryptophan (L-Trp) can be accounted for by the sequential, ordered binding of O2 and L-
Trp. Analysis of the data shows that at low concentrations of L-Trp, O2 binds first followed by the binding of L-Trp; at higher
concentrations of L-Trp, the order of binding is reversed. In addition, we show that the heme reduction potential (Em
0) has a
regulatory role in controlling the overall rate of catalysis (and hence the extent of inhibition) because there is a quantifiable
correlation between Em
0 (that increases in the presence of L-Trp) and the rate constant for O2 binding. This means that the initial
formation of ferric superoxide (Fe3+−O2
￿−) from Fe2+-O2 becomes thermodynamically less favorable as substrate binds, and we
propose that it is the slowing down of this oxidation step at higher concentrations of substrate that is the origin of the inhibition.
In contrast, we show that regeneration of the ferrous enzyme (and formation of NFK) in the final step of the mechanism, which
formally requires reduction of the heme, is facilitated by the higher reduction potential in the substrate-bound enzyme and the
two constants (kcat and Em
0) are shown also to be correlated. Thus, the overall catalytic activity is balanced between the equal and
opposite dependencies of the initial and final steps of the mechanism on the heme reduction potential. This tuning of the
reduction potential provides a simple mechanism for regulation of the reactivity, which may be used more widely across this
family of enzymes.
■ INTRODUCTION
Indoleamine 2,3-dioxygenase (IDO) catalyzes the first and rate-
limiting step in the kynurenine pathway, the O2-dependent oxida-
tion of L-tryptophan (L-Trp) to N-formylkynurenine, through
cleavage of the C2−C3 bond of the substrate, Scheme 1. The
mechanism of action of this dioxygenase activity is of increasing
interest from a clinical perspective because tryptophan catabo-
lism generates a number of secondary metabolites that are im-
plicated in a wide range of neurological disorders, cataract formation,
and suppression of T cell proliferation.
1 This extends to an
understanding of enzyme inhibition, because the development
of dioxygenase inhibitors is ongoing,
2 with some compounds in
clinical trials.
3
It was noted 40 years ago that the rate of tryptophan turn-
over in rabbit indoleamine 2,3-dioxygenase decreases at higher
concentrations of substrate.
4,5 There have been several pro-
posals for the origin of the inhibition by L-Trp, but a consensus
has not been reached. It was originally assumed
4 to be a result
of binding L-Trp to the ferric form of the enzyme. However,
there are two difficulties with this interpretation. First, we have
reported
6 for human IDO (hIDO) that binding of L-Trp to the
ferric enzyme leads to an increase in reduction potential of the
heme group; as we have noted previously,
7 early data reported
similar observations in rabbit IDO.
8,9 Such an increase in reduc-
tion potential would actually stabilize formation of the catalytically
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Scheme 1. Reaction Catalyzed by IDO
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lead to inhibition. Second, unlike other catalytic heme enzymes
which require continuous recycling of the oxidized ferryl heme, the
evidence so far indicates that only a single reduction of the ferric
heme is required in IDO, after which the reaction needs no further
reducing equivalents to proceed. Because of this, the binding of
L-Trp to ferric heme would not be expected to inhibit turnover
because ferric heme is not implicated catalytically.
In this contribution, we put forward an alternative hypothesis.
We show that the overall enzyme activity, and hence the extent
of the inhibition, is correlated with the heme reduction potential.
This provides a simple mechanism for regulation of enzyme
activity.
■ MATERIALS AND METHODS
Mutants of hIDO (S167H, S167A, F164A, F163A, F226A, F227A,
F226Y, R231K) were prepared using the QuickchangeTM Site-directed
Mutagenesis kit (Stratagene Ltd., Cambridge, UK). All variants were
sequenced to confirm that no spurious mutations had occurred during the
PCR and were expressed and purified according to previously published
procedures. Human IDO (hIDO) and all site-directed variants were
purified according to previously described procedures.
10 The variants
fall into the following three main categories: (i) those in which a
potential hydrogen-bonding residue is removed (Ser167 variants); (ii)
those which affect the hydrophobic nature of the heme pocket (Phe
variants); and (iii) those which affect hydrogen bonding to L-Trp
11
(Arg231 variant). His-tagged proteins were loaded onto a Ni-affinity
column in 50 mM potassium phosphate buffer, pH 8, containing 0.3 M
KCl, washed with the same buffer at pH 6, and then eluted with
0.25 M EDTA, pH 8. Eluted protein was loaded onto a Superdex 75
column (GE Healthcare) equilibrated with 0.1 M Tris HCl buffer, pH
8.3, containing 0.3 M KCl. Eluted fractions of pure protein had Soret
peak at 404 nm. All kinetic experiments were carried out in 0.1 M Tris
HCl buffer, pH 8, at 20.0 °C. Steady-state assays were carried out
using methylene blue, ascorbate and catalase for reduction of heme as
described previously
10 using a Perkin-Elmer Lambda 25 spectropho-
tometer. NFK formation was monitored at 321 nm and values of
kcat were extracted from initial rates (ΔAbs/min) by dividing by the
absorption coefficient for NFK (ε321 = 3.75 mM−1 cm−1) and the
enzyme concentration. Reduction potentials were determined by the
reduction of a dye with a known potential, according to published
procedures.
10 Typically, the assay solution contained potassium phos-
phate buffer (0.1 M, pH 7.0), glucose (5 mM), xanthine (300 μM),
xanthine oxidase (50 nM), glucose oxidase (50 μg/mL), catalase (5 μg/
mL), enzyme (2 μM), and the appropriate dye. Spectral changes were
monitored using a Perkin-Elmer Lambda 25 spectrophotometer
(the components glucose, glucose oxidase, and catalase being used
to generate an oxygen-free environment). Heme reduction potentials
were determined by fitting the data to a Nernst equation for a single-
electron process. All potentials are stated versus the normal hydrogen
electrode (NHE). The dyes, all supplied by Sigma-Aldrich, were:
phenosafranine (E0
m = −252 mV), nile blue (−116 mV), methylene
blue (+11 mV), toluidine blue (+34 mV).
12 Stopped-flow experiments
were carried out using an Applied Photophysics SX.18MV stopped-
flow spectrometer housed in an anaerobic glovebox (Belle Technology
Ltd., [O2] < 5 ppm) and fitted with a Neslab RTE-200 circulating
water bath (±0.1 °C). Reactions were monitored in single wavelength
mode (416, 576 nm) or using diode array. Reported values of kobs were
an average of at least four measurements, and all reactions were carried
out under pseudo-first-order conditions. Data were collected over a period
of 1 s from the mixing event, and traces were fitted to a single exponential
process to give kobs measured at different O2 concentrations. For O2 bind-
ing experiments, reactions were initiated by mixing anaerobic solutions of
enzyme (typically 2 μM, degassed with N2 a n dp r e r e d u c e dw i t hd i t h i o n i t e )
with an equal volume of fully degassed buffer containing O2 at different
concentrations (0.05−0.6 mM, prepared by mixing with a fully O2-saturated
solution of the same buffer). Equilibrium binding constants, Kd,f o rb i n d i n g
of L-Trp to ferrous enzyme (prepared by stoichiometric reduction with
dithionite) were determined anaerobically in the presence of glucose (5 mM),
glucose oxidase (50 μg/mL), and catalase (5 μg/mL).
■ RESULTS
Methodological Approach. The rate of catalytic turnover
of IDO decreases at higher concentrations of L-Trp.
4,5 This
has been observed for rabbit IDO
4 and more recently for
hIDO.
13,14 In this analysis, we have interpreted the behavior
according to Scheme 2. In this general mechanism, it is pro-
posed that O2 binds first (k1), which through oxidation of the
heme leads to the equivalent resonance form of ferric super-
oxide (Fe3+−O2
￿−). There is evidence for the presence of a
ferric superoxide species from recent resonance Raman work,
15
which is consistent with the same formulation of this ferrous-
oxy bond in the globins (see for example ref 16). This is followed
by binding of L-Trp (k3), leading to the formation of the ternary
complex (Fe3+−O2
￿−−Trp), which subsequently converts to pro-
duct with the rate constant kcat. Scheme 2 dictates that under
conditions where the concentration of L-Trp is very high (e.g., for
enzyme inhibition), L-Trp will bind to the protein (k2)b e f o r eO 2
(k4), such that the same ternary complex forms product and the
resting enzyme is recovered (with the same rate constant, kcat).
We first analyze inhibition data obtained in this work accord-
ing to Scheme 2, to extract the relevant inhibition constants.
We go on to show that these inhibition constants depend on
both k1 and kcat, and that k1 and kcat themselves are oppositely
correlated with the reduction potential of the heme group. We
probe these effects further with a number of mutants, Figure 1,
which were selected with the aim of probing active-site struc-
ture and varying the heme reduction potential. We use this
Scheme 2. Mechanistic Scheme Used for Analysis of Substrate Inhibition
Figure 1. Active-site structure in hIDO, showing the locations of the
residues targeted by mutagenesis in this work.
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regulated by the reduction potential in wild-type hIDO and
numerous site-directed variants.
Substrate Inhibition. Derivation of Relevant Equations.
The rate of catalytic turnover of hIDO decreases at higher con-
centrations of L-Trp, as shown in Figure 2 for hIDO. The
derivations from the initial steady-state approximation are pre-
sented in the Supporting Information (derivation 1), giving rise
to the following expression for the rate of the reaction, eq 1
(which is Eqn S8 in the Supporting Information):
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As we explain in the Supporting Information and again be-
low, this expression is useful because it accommodates different
kinds of inhibition.
If kcat ≪ k1[O2], which is expected to be the case because kcat
is typically <20 s−1 for dioxygenases in general (and only ∼1s −1
for hIDO), and because k1 is ∼106 M−1 s−110, then the Michaelis
constant, KM, is defined as in eq 2.
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In eq 1, there are two effective substrate inhibition constants,
Ki
eff and Ki
eff,1. These constants have complicated expressions
(see Supporting Information); however, they can be approxi-
mated by eqs 3 and 4 to correctly account for the limiting cases
of strong and weak inhibition, so that,
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where Kd is the binding constant of L-Trp to ferrous hIDO
(Scheme 2, Kd = k−2/k2), and
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where k̃
4 is defined as the overall (observed) rate of product
formation (from the consecutive reactions) if L-Trp binds first
(depicted as “route 2” in Scheme 2)
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For eq 1 there are three types of behavior, each of which we
have observed in our experiments and which can be rationalized
with different ratios of Ki
eff and Ki
eff,1, see also Supporting
Information (SI) (Derivation 1). Type 1 behavior shows full
inhibition of the steady-state rate, as observed for hIDO (Figure 2)
and F227A (Table 1), with the effective inhibition constant Ki
eff
Figure 2. Plots of rate (ΔAbs min−1) versus substrate concentration
for hIDO (■) and the S167A variant of hIDO (△). Lines show fits of
the data to eq 1; steady-state parameters extracted from the fit are listed in
T a b l e1 .C o n d i t i o n s :0 . 1MT r i s - H C l ,p H8 . 0 ,[ e n z y m e ]=1 0 0n M ,
30 μg/mL catalase, [ascorbate] = 20 mM, [methylene blue] = 10 μM,
[O2] = 258 μM, 20.0 °C.
Table 1. Summary of Reduction Potentials and Steady-State and Presteady-State Constants for hIDO and Site-Directed Variants
a
protein E0
m (Fe2+/Fe3+) (mV)
f kcat (s −1) KM (μM) Ki
eff (μM)
d Kd (μM)
g Ki
eff
(calc) (μM)
h Ki
eff,1 (μM) k1 (μM −1 s −1)
i,k
hIDO
b −60 1.4 ± 0.1 5.0 ± 0.3 65 ± 6 0.7 ± 0.2 68 − 0.53 ± 0.03
j
S167A
c −12 1.6 ± 0.1 22 ± 23 1 ± 2 0.7 ± 0.2 29 400 ± 100 0.25 ± 0.01
S167H −200 0.0060 ± 0.0003 26 ± 3 −− 10000 −−
F163A
c −119 0.040 ± 0.002 68 ± 6 1700 ± 100 0.4 ± 0.1 2700 >10000 0.78 ± 0.04
F164A
c −85 0.68 ± 0.03 160 ± 10 400 ± 20 −− 1300 ± 200 −
F226A
e −127 0.12 ± 0.01 310 ± 20 1000 ± 50 0.4 ± 0.1 750 970 ± 100 1.00 ± 0.05
F226Y
c 18 6.0 ± 0.3 160 ± 10 10 ± 1 0.7 ± 0.2 5.0 98 ± 10 0.17 ± 0.01
F227A
b −116 0.40 ± 0.02 15 ± 2 − 0.2 ± 0.1 93 − 0.76 ± 0.04
R231K
e −106 0.30 ± 0.01 −− 0.2 ± 0.1 410 − 0.70 ± 0.03
aThe reduction potential for hIDO was previously published.
10.
bFor this type of inhibition the rate goes to zero (Type 1, full inhibition), and Ki
eff,1
is out of experimental range (i.e., >10,000 μM); see eqn S8 in SI.
cFor this type of inhibition, Ki
eff and Ki
eff,1 are comparable (eq 1), and partial inhibi-
tion is observed (Type 3).
dIn some proteins, it was not possible to obtain reliable sets of inhibition data either because the enzyme was not stable
enough under conditions of high concentration of tryptophan (for R231K and F227A) or because the steady-state activity is very low to begin with
(for S167H). This means that values for inhibition constants (Ki
eff) could not be obtained (see Figure 5).
eFor this variant no inhibition is observed
(Type 2). Both Ki
eff and Ki
eff,1 are large and out of experimental range. Normal Michaelis−Menten kinetics are therefore observed.
fFor reduction
potentials, estimated errors of ±2 mV apply in all cases, which is largely a consequence of the uncertainty of the measured (literature) potential of
the reference dye.
gIn some cases, it was not possible to determine a value for Kd because the absorbance changes were too small (for Kd).
hCalculated using eq 3.
iAll second-order rate constants for O2 binding, k1, were determined experimentally by stopped flow (from a linear
dependence of kobs on [O2]), except for the value presented for hIDO which has been reported previously.
10 jThe second-order rate constant in the
presence of L-Trp was observed to be lower (k4 = 0.16 ± 0.02 μM−1 s−1).
kIn some cases, it was not possible to determine a reliable value for k1
because the ferrous oxy species was either unstable (F164A, S167H) or found not to be formed in 100% yields (S167H).
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can exceed the magnitude of Ki
eff.I nt h i sc a s e ,Ki
eff is within experi-
mental range, kcat approaches zero at the limiting concentration
of L-Trp, and Ki
eff,1 is (infinitely) large and is not experimentally
accessible. Type 2 behavior occurs when Ki
eff itself is not experi-
mentally accessible (i.e. Ki
eff ≫ [L-Trp]). In this case, no inhibition
is observed, and kcat does not decrease with increasing concen-
tration of substrate, an example being the F226A variant, Figure
S1(SI). Type 3 behavior is when kcat reduces in value but does not
approach zero, for example for the F226Y variant, Figure S1(SI),
the S167A variant (Figure 2), and the F163A, F164A variants,
Table 1. In this case, the additional constant Ki
eff,1 (which can be
considered as the concentration of L-Trp at which the rate of
product formation through routes 1 and 2 in Scheme 2 becomes
equal, see derivation 2 in SI) is within experimental range (i.e., not
infinitely large as above) but takes into consideration our observa-
tions for certain variants that the reaction may not always approach
zero at high concentrations of L-Trp. In these cases partial
inhibition is seen, because turnover is slowed down but can still
proceed at a measurable rate even when L-Trp binds first (route
2 in Scheme 2, where k4 ≠ 0). One can see from eqs 1, 3, and 4
that in extremis, when the concentration of L-Trp is larger than
either that of Ki
eff or Ki
eff,1, then the reaction rate is k̃
4 [hIDO]
and that under these conditions of high tryptophan concen-
tration, from eq 5 one can see that k̃
4 is small and approximates
to k4[O2] when kcat > k4[O2]. The latter condition dictates that
with binding of O2 to the Fe2+−Trp complex, k4 must be
slowed down in the presence of the substrate, which is the
ultimate reason for the inhibition.
Data Analysis. Figure 2 shows the results of the substrate
inhibition experiments for hIDO and an analysis of the experi-
mental data according to Scheme 2 and fitted to eq 1. Best-fit
values for the parameters kcat, KM, Ki
eff,a n dKi
eff,1 are shown in
Table 1 along with the reduction potential for hIDO (previously
reported
10). The corresponding fitted values for a number of site-
directed variants are also presented in Table 1.
The validity of the fitting process can be verified because the
extracted values for Ki
eff can be calculated independently from
other experimentally accessible constants, as Ki
eff is itself the
product of two terms, eq 3. The first, Kd, is the binding con-
stant of L-Trp to ferrous hIDO (Kd = k−2/k2, Scheme 2), which
was determined by anaerobic titration of reduced enzyme with
L-Trp, Table 1. The second comes from the ratio k1[O2]/kcat,
where [O2] is constant (258 μM). Where reliable experimental
values are available for k1, values for Ki
eff can thus be calculated
independently from Kd, k1 and kcat (eq 3) and compared with
the experimental values. For instance for hIDO, kcat = 1.35 s−1
(Table 1), k1 = 0.53 μM−1 s−1,
10 and Kd = 0.7 μM, which yields
Ki
eff =6 8μM. This is close to the value derived experimentally
(Ki
eff =6 5μM, Table 1). Other calculated values for Ki
eff are
shown in Table 1, and are likewise in good agreement with the
experimental data. In general, less active hIDO variants have smaller
values of kcat w h i c hl e a dt ol a r g e rv a l u e sf o rKi
eff according to eq 3,
which accounts for the fact that substrate inhibition is not observed
with these mutants (Type 2 behavior): F163A is an example, as
Ki
eff is in the millimolar range and therefore inaccessible experi-
mentally. Overall, these analyses show that reliable values for
Ki
eff can be extracted (in the range of 5 μM to 2 mM) and that
the experimental values are in reasonable agreement with
calculated values.
Dependence of k1 on Reduction Potential. We have
reported
10 the reduction potential (E0
m (Fe3+/Fe2+) of hIDO
as −63 mV (substantially lower than typically observed in the
globins
17,18) and that binding of L-Trp to hIDO increases the
reduction potential to +18 mV in the presence of the substrate.
In that work,
10 we made the preliminary observation that second-
order rate constants for binding of O2 to ferrous hIDO are
affected by changes in the reduction potential of the heme
group introduced by mutation. In particular, the S167A variant
(E0
m (Fe3+/Fe2+)=−12 mV, which is 50 mV higher than
hIDO), has a second-order rate constant for O2 binding (k1 =
0.25 μM−1s−1) that is 2-fold slower than that observed for hIDO
(k1 =0 . 5 3μM−1 s−1), and the correlation between the rate con-
stants is according to the expected dependence of the rate
constant for Fe2+ oxidation on the reduction potential (because
the oxy ferrous intermediate converts by oxidation to ferric
superoxide), eq 6.
+→ − ++ • − Fe O Fe O 2
2
3
2 (6)
The following expression applies,
=− α ++ kE R T lnc o n s t ( F e / F e ) / 1
0
m
32
(7)
where 0 < α < 1 is the Marcus transfer coefficient,
19 and
RT(= RT/F) = 25 mV at T =2 0°C.
a As we show in the SI
(derivation 2, Eqn SC), a linear expression can be derived by
equating the two expressions for the wild type and variants. We
present data for hIDO and a number of variants plotted in this
way according to Eqn SC, Figure 3. The reduction potentials
used in these analyses are presented in Table 1, with a re-
presentative data set shown for the F226Y variant in Figure S2
(SI); second-order rate constants for O2 binding, k1, are also
reported in Table 1, with representative data sets shown for the
F227Y variant in Figure S3 (SI). A linear correlation of ln k1
against reduction potential is observed across the range of
variants, Figure 3, although there is some scattering of points.
The average slope is calculated as α = 0.28, which is consistent
with the analysis and discussed further below. To our knowledge,
this dependence of the rate constant for O2 binding with
reduction potential appears to have been overlooked in previous
studies.
Applying the same rate constant/reduction potential correla-
tion, according to Scheme 2, one can predict that when L-Trp
binds first the positive shift in potential (81 mV for hIDO
10)
Figure 3. Logarithmic dependence of k1 (see values given in Table 1),
normalized to k1 (hIDO), on the difference of the reduction potentials
between the corresponding variant Em
0 (Fe3+/Fe2+) and hIDO (Em
0
(Fe3+/Fe2+ (hIDO)). The F164A variant is not included in this plot
because the stability of its ferrous oxy was too low to allow a meaning-
ful determination of k1 (see also data in Table 1).
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Trp complex (k4) according to eq 7, because the formation of
ferric-superoxide heme from oxidation of ferrous oxy heme is
redox driven and can be analyzed as such. Accordingly, when
the Fe3+/Fe2+ potential is increased, the rate constant k4 is ex-
pected to decrease, and one can predict that it slows down by
exp(−α((E0
m (Fe3+/Fe2+) − E0
m (Fe3+−Trp/Fe2+−Trp))/RT)=
exp(0.24 × 81/25) = 2.1 times. This conclusion is verified
by stopped-flow experiments in which formation of FeII−O2
(monitored at 570 nm) was faster in the absence of tryptophan
(k1= 0.53 ± 0.06 μM−1 s−1) than after preincubation of ferrous
hIDO with L-Trp (k4 = 0.16 ± 0.02 μM−1 s−1, Table 1). The
experimentally determined ratio k1/k4 = 3.3 is in good agree-
ment with the predicted value of 2.1 calculated from the shift in
the reduction potentials.
Dependence of kcat on Reduction Potential. In the pre-
ceding section we have shown that the kinetics of O2 binding to
ferrous hIDO were correlated with the reduction potential of
the heme iron, Figure 3, as described by eq 7. One can further
expand this approach and also consider the rate-determining
final step (kcat) in Scheme 2 as a redox process because it
involves formal “re-reduction” of the heme, eq 8.
b
−−→ +− +− + Fe O Trp Fe [O Trp] 3
2
2
2 (8)
When considering this as an electrochemical process, a
similar expression for the rate constant can be proposed, eq 9.
=+ − α ++ kE R T lnc o n s t ( 1 ) ( F e / F e ) / cat
0
m
32
(9)
This shows that the dependence of kcat on reduction potential is
also exponential (as it is for k1 in eq 7), but there is an impor-
tant difference: the transfer coefficient must be 1 − α, since it is
the reverse reaction that is being considered. Experimental veri-
fication of this requirement imposes a crucial check on the validity
of the model.
The experimental data for hIDO and a number of variants are
shown in Figure 4, where plots of ln kcat for each variant (using
a derivation similar to k1 above, see Supporting Information, Eqn
(SD)) are shown as a function of the corresponding difference in
the reduction potential between hIDO and the variant (Table 1).
The dependence fits a linear function according to eq 9. Moreover,
the transfer coefficient (from the slope) is 1− α = 0.76 according
to eq 9. This means that α = 0.24 which is in very good agreement
with the estimate of α = 0.28 from the O2-binding experiment
shown in Figure 3 (above), providing a reliable test of the
methodology.
Overall Dependence of Enzyme Inhibition (Ki
eff)o n
Reduction Potential. The above analyses for k1 and kcat show
that they are oppositely correlated with the heme reduction
potential, Figures 3 and 4. But both of these terms contribute to
the inhibition constant, Ki
eff, extracted from Figure 2, because
Ki
eff = Kdk1[O2]/kcat, eq 3). From eq 7 for k1 and eq 9 for kcat,
one sees that the transfer α coefficient cancels, since k1/kcat ≈
exp(−αE0
m(Fe3+/Fe2+)/RT)/exp((1 − α)E0
m(Fe3+/Fe2+)/RT)=
exp(−E0
m(Fe3+/Fe2+)/RT).
Combining the pre-exponential factors into a single potential
independent constant, one derives eq 10:
=−
++
K
E
RT
lnc o n s t
(Fe /Fe )
i
eff m
03 2
(10)
which gives an expression for the overall dependence of Ki
eff
on the reduction potential, which is contributed by the equal and
opposite effects of the dependence of k1 and kcat on the reduction
potential. As above for k1, a linear expression can be derived by
equating the two expressions for the wild type and variants
(derivation 2 in SI, Eqn SE). Accordingly, a logarithmic plot of
Eqn SE, Figure 5, is expected to be linear. The data show that this
is indeed the case, and the slope (= 0.86 ± 0.05) is close to unity
which means that the assumptions leading to eq 10 are correct.
c
■ DISCUSSION
Substrate inhibition of IDO has long been a feature of the
literature,
5,20 but the mechanism of inhibition has not been
established. It has been suggested
4 to originate from the un-
productive binding of L-Trp to the catalytically inactive ferric form
of the enzyme. However, in 2005 we noted
6 that the reduction
potential for human IDO (hIDO) increases on binding of L-Trp,
and this is not consistent with such an interpretation.
Origin of the Inhibition. Recently, it has been proposed
from steady-state analyses
13 that a second binding site for L-Trp
is the source of the inhibition in hIDO. There may indeed be a
second (weak) binding site,
13,14,21 a n da th i g he n o u g hc o n c e n t r a t i o n s
Figure 4. Logarithmic dependence of kcat, normalized to kcat (hIDO),o n
the difference of the reduction potentials between the corre-
sponding variant Em
0 (Fe3+/Fe2+)a n dh I D OEm
0 (Fe3+/Fe2+
(hIDO)). See also data in Table 1 (and footnote k).
Figure 5. Logarithmic plot of the dependence of Ki
eff (Table 1),
normalized to Ki
eff
(hIDO), on the difference of the reduction potentials
between the corresponding variant Em
0 (Fe3+/Fe2+) and hIDO Em
0
(Fe3+/Fe2+ (hIDO)). See also data in Table 1 (and footnote d).
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multiple conformations
22 within the distal cavity (although
spectroscopic data suggest that multiple conformations of
substrate orientation are not likely in the presence of O2
23). We
do not exclude the possibility of a second site at high con-
centrations of Trp, most likely above those found physiolog-
ically, but we can account for the inhibition without needing
to invoke binding at a second, inhibitory site (physiological
concentrations of tryptophan are not well documented but are
probably in the range 40−100 μM
24,25). Indeed, the crystal
structure of hIDO shows two CHES molecules in the active
site, which might be an indication of a larger, more open active
site. However, a fit of kinetic inhibition data to this kind of
dependence does not, ipso facto, establish the existence of a
second site. We find that substrate inhibition in hIDO can be
rationalized by assuming only a single binding site for L-Trp for
the wild-type protein and all variants. We do not exclude the
possibility of a second site at high concentrations of Trp (most
likely above those found physiologically), but we can account
for the inhibition without needing to invoke binding at a second,
inhibitory site. Our analyses go beyond just the fitting of steady-
state inhibition data and include an examination of the effect of
reduction potential on both O2 binding (k1) and turnover (kcat).
We have demonstrated that the inhibition constant is correlated
first with k1, Figure 3, and oppositely with oppositely with kcat,
Figure 4 (as well as with Kd) and that the reduction potential
dependence of the inhibition constant is exactly correlated with
the expected reduction potential dependence of both k1 and kcat
across a range of variants. There are essentially three types of
inhibition behavior, Scheme 2.
(i) In the case of normal substrate inhibition (e.g., for the wild-
type protein and also F227A, Type 1) O2 binds first fol-
lowed by binding of L-Trp. This means that at low substrate
concentrations the rate of the first step (formation of ferric
superoxide (= k1[Fe2+][O2])) is fast and product formation
occurs through “route 1” of Scheme 2; under conditions
of high L-Trp concentrations, L-Trp binding out-competes
O2 binding, but then formation of the ternary complex
(= k4[Fe2+−Trp][O2]) becomes rate limiting and, in
extremis, approaches zero (Type 1 inhibition).
(ii) In the case where no substrate inhibition is observed
(Type 2, e.g. for F226A and R231K), either O2 (k1)o r
Trp (k2) can bind first, but binding of Trp (“route 2” in
Scheme 2) does not block activity at all, so that no
inhibition is observed (k1 ≈ k4).
(iii) In cases where partial inhibition (Type 3) is observed
(e.g., S167A, F163A, F164A, and F226Y), binding of
substrate at high concentrations reduces but does not
completely block activity, so that the reaction can still pro-
ceed by both routes productively and slows down at high con-
centrations of substrate but not to zero (k1 > k4,a n dk4 ≠ 0).
This analysis can account for the long-documented
4,5 lack of
inhibition (reproduced recently
13) seen for IDO against D-Trp,
because if Kd for D-Trp binding in IDO is larger than for L-Trp
(as it is, for example, in human TDO
7) then Ki
eff is correspond-
ingly large (eq 3) and out of range, and no inhibition is expected.
The analysis also accounts for the fact that hTDO does not show
substrate inhibition at all.
7,26 Rather than exhibiting preferential
binding of substrate to the reduced enzyme (as observed by us
6
and others
14 in hIDO), binding of L-Trp to ferrous hTDO is
much weaker
7,26 which again may be understood in terms of
our proposed model, because increases in Kd will correspond-
ingly increase Ki
eff, so that substrate inhibition is not observed.
A Quantitative Correlation of Older Data. The analysis
also helps to clarify several older reports in the published litera-
ture. A qualitative correlation between activity and the electron-
withdrawing capacity (which can be considered as correlated
with the reduction potential) of heme had been noted pre-
viously, but its implications had not been quantified or widely
appreciated. It was shown some years ago
27 that the logarithm
of the turnover rate is linearly correlated with reduction poten-
tial in TDO reconstituted with variously substituted heme pros-
thetic groups (which have different reduction potentials). But
the experiments were carried out on different enzymes, which
meant that the observations were correlated only qualitatively,
with the authors simply noting that “the catalytic activity of
L-tryptophan 2,3-dioxygenase increases as the affinity of the
enzyme for oxygen increases”. This is precisely the behavior
that we describe, and so we have used our eqs 7 and 9 to
quantify the previously published data.
27 If we take the pre-
viously published values
27 for kcat (for TDO) and the binding
constant of the ferrous enzyme for O2 and reanalyze the
original data in the same way as we have done above for IDO,
we observe the expected logarithmic dependence (with one
rogue data point in each case, Figure 6). This analysis further
supports our conclusions, and the two sets of experiments can
in fact be regarded as similaron the one hand by changing reduc-
tion potential by substitution of the heme group
27 and on the other
by mutation (this work)but giving the same overall correlation.
pH-Dependence of Substrate Inhibition. Our analyses
also help to clarify other aspects of the older literature.
4 First,
Sono and co-workers
4 have shown for rabbit IDO that sub-
strate inhibition is stronger at higher pH (Figure 6 in ref 4)
and separately that there is a decrease in Kd for L-Trp bind-
ing to ferrous IDO with increasing pH (Figure 5 in ref 4,
which is the same dependence as that observed for hIDO
6).
Figure 6. Plots of previously published
27 data (taken from Table 1 of ref 25) showing (A) ln Vmax and (B) ln K50(O2) for heme-substituted TDO as a
function of reduction potential of the corresponding heme. Vmax is the maximal turnover rate, and K50(O2) is the O2 affinity.
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constant Ki
eff is proportional to Kd so that the observed
4 decrease
in Kd at higher pH leads directly to a corresponding decrease in
Ki
eff, thus accounting for the stronger inhibition.
Second, it was concluded
4 that inhibition was caused by
binding of Trp to the ferric enzyme because the inhibition
constant was found to be of a magnitude similar to that of the
Kd for binding of L-Trp to ferric enzyme (i.e., in the millimolar
range). This seems unlikely, because in fact Ki
eff (Table 1) is
less than 100 μM, which is much lower than the binding con-
stant for Trp binding to ferric enzyme (most recent deter-
minations put the Kd for L-Trp binding to ferric enzyme as very
much higher, in the millimolar range
6,13,14,28). Our model resolves
this problem, because it implicates Kd only for the ferrous enzyme.
The inhibition constant, Ki
eff,i se q u a lt oKd multiplied by the
factor k1[O2]/kcat,e q3 ,w h i c hs h i f t st h ev a l u eo fKd for the
ferrous enzyme to a much higher value (from the submicromolar
range to much higher (tens of micromoles)), and therefore
in close agreement with the values for Ki
eff. As we explained in
the Introduction, there are other conceptual problems with the
idea that binding of L-Trp to ferric enzyme is the source of the
inhibition.
■ CONCLUDING REMARKS
There has been considerable confusion in the literature on the
order of substrate binding in the dioxygenases. In hIDO at least,
our data clearly indicate that O2 binding precedes Trp binding
because if this binding order is reversed the increase in reduc-
tion potential as a consequence of Trp binding disfavors the
subsequent O2 binding step. There is an informative analogy
here with the P450s. In the P450s, substrate binding can also be
accompanied by an increase in reduction potential of the heme,
although in this case the substrate binds to ferric heme, and the
increase in potential facilitates the subsequent reduction and
turnovera molecular ‘gate’ that needs to be ‘opened’ during
every turnover cycle. In IDO, there is no need for continuous
reduction of the heme because only a single (initiating) re-
duction is required. Consequently, the increase in reduction
potential on substrate binding in IDO is not used in the same
way; instead, the increase in reduction potential stabilizes the
ferrous form and slows down O2 binding. We propose that this
is the source of the inhibition at high substrate concentrations,
thus dictating that O2 binds first.
■ ASSOCIATED CONTENT
* S Supporting Information
The derivation of relevant equations, steady-state data for
variants (Figure S1) and representative reduction potential
(Figure S2) and O2 binding (Figure S3) data. Complete ref 11.
This material is available free of charge via the Internet at
http://pubs.acs.org.
■ AUTHOR INFORMATION
Corresponding Author
emma.raven@le.ac.uk
■ ACKNOWLEDGMENTS
This work was supported by grants from The Wellcome Trust
(083636 to E.R. and to S.K.C./C.G.M.) and EPSRC (student-
ship to N.C.).
■ ADDITIONAL NOTES
aIn all calculations for variants we assume that the “const” in
eq 7) (and in eq 9) is not altered by the mutations,
so that only the reduction potential is changed. To simplify
formulas, we use RT instead of RT/F in all cases (which is
equivalent, if it is measured in mV).
bIn eq 8, the formation of the product NFK is shown
schematically as [O2−Trp] to allow only the charge transfer
processes to be easily visualized.
cThe finding that α = 0.28 is conserved for k1 and kcat (where it
is 1 − α, with α = 0.24) reflects the fact that both reactions have
the same geometry of transition state, in which charge is
redistributed between iron and oxygen.
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